1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Actual deadline was March 25, 2025; stored deadline of 2026-03-25 appears to be exactly one year off — the challenge has already closed
Reducing the Burden of Preeclampsia is sponsored by Gates Foundation Trust. Seeking innovative solutions for the early detection, prevention, and treatment of preeclampsia. The challenge focuses on identifying biomarkers to predict risk, developing point-of-care tests, and leveraging digital health or nutritional interventions to reduce maternal and neonatal morbidity and mortality, particularly in resource-limited settings.
Geographic focus: Global (priority for low- and middle-income countries)
Focus areas: Maternal Health, Diagnostics, Global Health
Get alerted about grants like this
Get emailed when new opportunities from “Gates Foundation Trust” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Reducing the Burden of Preeclampsia Before applying, applicants should familiarize themselves with the supporting documents for this Grand Challenge , including the terms and conditions of the Gates Foundation , the Rules and Guidelines , Application Instructions , and Frequently Asked Questions . If you are planning to apply to this RFP, we will be hosting a dedicated webinar on February 27, from 7:30 to 8:30 AM Pacific Time .
This session will provide a comprehensive overview of the RFP details and an opportunity to have your questions answered. To participate in the webinar, please register and submit your questions in advance . If you cannot attend live, the webinar will be recorded and available on this challenge page after the session.
Preeclampsia is a leading cause worldwide of maternal morbidity and mortality, premature birth, stillbirth, and neonatal death. Preeclampsia is a placental disease caused by two different pathologies during pregnancy. Early-onset disease, caused by reduced uteroplacental blood supply, is a major driver of fetal mortality.
Late-onset disease, caused by increased fetoplacental demands, is a major driver of maternal morbidity and mortality. These two pathologies converge on elevated levels of the protein sFlt1 and concomitant decreases in PlGF. This mechanistic understanding is being translated into new strategies to reduce the burden of preeclampsia.
Therapeutic candidates are being developed that target sFlt1 activity, and levels of this protein can be used in screening for preeclampsia risk. Effective screening and low-dose aspirin therapy early in pregnancy has been shown to prevent early-onset preeclampsia and to ameliorate the disease's consequences for the fetus.
Despite the growing understanding of preeclampsia biology, questions remain about heterogeneity of the disease across patients and the degree to which there are distinct subtypes and etiologies. New approaches are also needed to more quickly and comprehensively reduce the burden of preeclampsia, especially those suitable for the health care infrastructure in the countries with the highest burden.
We seek proposals for innovative solutions for the early detection, prevention, and treatment of preeclampsia, particularly in low- and middle-income countries where maternal mortality rates are high.
To support this focus, we are looking for collaborations, including those with research institutions, health care providers, and global health organizations, that enable cross-sector insights and ensure that solutions are adaptable and practical. The objectives of the challenge are: Early prediction and detection of preeclampsia .
We seek novel biomarkers as well as novel approaches to measurement of sFlt1 and PlGF, diagnostic tests, and point-of-care technologies to predict early in pregnancy the risk of preeclampsia and to diagnose it before symptoms become severe. Understanding the pathophysiology of preeclampsia and its heterogeneity .
We seek to understand the biological mechanisms driving the disease and its subtypes so that new interventions can be effectively tailored to the underlying etiology. Preventive and therapeutic interventions . We seek new approaches to known targets or new targets to reduce the incidence and severity of preeclampsia, mitigate disease progression, and prevent the cardiovascular and metabolic complications that often follow it.
We will consider proposals for awards of up to $500,000 USD for each project, with a grant term of up to 2 years. Application budgets should be commensurate with the scope of work proposed. Indirect costs will be considered, and should be included in the budget for the up to $500,000 USD award (subject to the Gates Foundation's indirect cost policy ).
This initiative is open to nonprofit organizations, for-profit companies, international organizations, government agencies, and academic institutions. We particularly encourage applications involving projects led by women or from women-led organizations and applications from institutions based in low- and middle-income countries.
We are looking for proposals that: Identify biomarkers that easily, reliably, and affordably predict preeclampsia risk early in pregnancy Identify biochemical, genetic, epigenetic, or metabolomic signatures that can be translated into point-of-care tests Leverage innovations in mobile health, wearable sensors, or simple clinical algorithms to identify women at risk before symptoms become severe Identify the underlying biological mechanisms driving preeclampsia and its subtypes, including the roles of the placenta, endothelial function, immune response, and gut microbiota Identify preventive interventions synergistic with or additive to low-dose aspirin, such as nutritional, pharmacological, or lifestyle-related approaches to reduce the incidence or severity of preeclampsia Identify new drug candidates, therapeutics, or repurposed medications that safely mitigate preeclampsia progression without harming the fetus We will not fund proposals that: Focus on implementation science, health systems integration, or social determinants (although these are all important elements, they are not in the scope of this request for proposals) Do not have the potential to become affordable and scalable in resource-limited settings Represent basic research without clear relevance to the objectives of this challenge Lack a clearly articulated and testable hypothesis Present unacceptable safety risks or detract from or interfere with beneficial practices Approaches that leverage previously failed biomarker exploration
According to the current listing, eligibility includes: Nonprofit organizations, for-profit companies, international organizations, government agencies, and academic institutions. Applications from women-led organizations and institutions in low- and middle-income countries are highly encouraged. Confirm the full requirements in the official notice before applying.
The current listing shows up to $500,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was March 25, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Reducing the Burden of Preeclampsia is funded by Gates Foundation Trust. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
MacKenzie Scott's Yield Giving has moved more than $26 billion — including roughly $7 billion in 2025, over a third of all U.S. megagifts — through unrestricted, trust-based grants with no application. Melinda French Gates's Pivotal Ventures has committed $2 billion to women's health and economic power. The Bezos philanthropies have moved billions more. As the Buffett–Gates era winds down, this new class of megadonor is rewriting the rules of major giving. Here is what changes for nonprofits, and how to become the kind of organization this money finds.
Read articleOn July 14, 2026, Warren Buffett routed his roughly $6 billion annual Berkshire gift to four family foundations and excluded the Gates Foundation — the first exclusion since 2006, pending a review of the foundation's historical ties to Jeffrey Epstein. Buffett has given the Gates Foundation more than $43 billion over two decades. Here is why the pause matters for the world's largest grantmaker, what it reveals about concentration risk in modern philanthropy, and what nonprofits that depend on a single major funder should do now.
Read articleFive of America's wealthiest philanthropists are spending $1 billion over 15 years on AI tools for frontline workers and low-income families. Here's what nonprofits and social enterprises need to know.
Read article